Business
Axsome Therapeutics Hosts Solriamfetol Virtual Investor Event with Expert Thought Leaders Today
NEW YORK, Dec. 07, 2023 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel therapies
About this update from Axsome Therapeutics, Inc.
[{"type":"text","content":"NEW YORK, Dec. 07, 2023 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous system (CNS) disorders, is hosting a virtual investor event and conference call today from 8 a.m. – 10 a.m. Eastern Time to provide an update on solriamfetol, a dual-acting dopamine and norepinephrine reuptake inhibitor (DNRI) and trace amine-associated receptor 1 (TAAR1) agonist. At the event, invited physician thought leaders will discuss current and potential future indications. The Axsome senior leadership team will provide an overview of clinical development plans. The presenters will be available to answer questions at the end of the presentations. To access the event, please click here. Expert thought leaders presenting at the event include: Craig Chepke, MD, Medical Director of Excel Psychiatric Associates in Huntersville, N.C. and Adjunct Associate Professor of Psychiatry for Atrium Health. Dr. Chepke will provide an overview of TAAR1 signaling and major depressive disorder (MDD).Andrew Cutler, MD, Clinical Associate Professor of Psychiatry SUNY Upstate Medical University. Dr. Cutler will provide an overview of attention deficit hyperactivity disorder (ADHD).Susan McElroy, MD, Chief Research Officer and Director of Psychopharmacology Research at the Lindner Center of HOPE at the University of Cincinnati. Dr. McElroy will provide an overview of binge eating disorder (BED).Richard Bogan, MD, Associate Clinical Professor at the University of South Carolina School of Medicine and at the Medical University of South Carolina in Charleston, S.C., and is Principal of Bogan Sleep Consultants. Dr. Bogan will provide an overview of the SHARP study of solriamfetol in patients with excessive daytime sleepiness (EDS) associated with obstructive sleep apnea (OSA), and impaired cognitive function.Charles Czeisler, MD, PhD, Baldino Professor of Sleep Medicine, Director of the Division of Sleep Medicine at Harvard Medical School and Chief of the Division of Sleep Medicine in the Department of Medicine at Brigham and Women’s Hospital in Boston. Dr. Czeisler will provide an overview of shift work disorder (SWD). Webcast and Conference Call Information A live webcast of the event can be accessed on the “Webcasts & Presentations” page of the “Investor...